At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 40 enrolled
Drug / intervention
Acalabrutinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1/2 Proof-of-Concept Study of the Combination of ACP-196 and ACP-319 in Subjects With B-cell Malignancies
In Brief
A Phase 2 clinical trial evaluating Acalabrutinib and ACP-319 for Non-Hodgkins Lymphoma and 2 related conditions. Completed, enrolled 40 participants across 7 sites.
Detailed Summary
This study is evaluating the safety, pharmacokinetics (PK), pharmacodynamics (PD), and efficacy acalabrutinib and ACP 319 in B-cell malignancies.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNon-Hodgkins Lymphoma, Multiple Myeloma, B-All
CountriesUnited States
CollaboratorsAstraZeneca
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
Enrollment StartDec 2014
First PostedDec 2014
Primary CompletionJun 2020
Study CompletionOct 2025
TodayJul 2026
First PostedDec 31, 2014
Enrollment StartDec 20, 2014
Primary CompletionJun 1, 2020
Study CompletionOct 30, 2025
TodayJul 2, 2026
Enrollment to primary: 5.4 yearsPosted 11.5 years ago
Interventions
Acalabrutinibdrug
Oral
ACP-319drug
Oral